Leukemia News

The FDA granted priority review to quizartinib for treatment of certain patients with acute myeloid leukemia.

Emerging evidence has shown chimeric antigen receptor T-cell therapies are highly effective regardless of a patient’s race or ethnicity.

Researchers have discovered a link between neurotoxicity related to chimeric antigen receptor T-cell therapy and development of subsequent hypophosphatemia.

A fourth dose of the COVID-19 vaccine increased humoral immunity among patients with solid and hematologic cancers, according to study results published in JAMA Oncology.

The basic science discoveries to which Helen E. Heslop, MD, DSc (Hon), has contributed place her firmly on the Mount Rushmore of pioneers in the field of gene and cell therapy.

Conception via assisted reproductive technology appeared associated with increased risk for childhood cancers compared with natural conception or subfertility and nonassisted reproductive technology conception methods, study results showed.

The FDA granted orphan drug designation to KITE-222, an investigational chimeric antigen receptor T-cell therapy, for treatment of adults with relapsed or refractory acute myeloid leukemia.

Anxiety and depression that may follow a cancer diagnosis, especially as a patient approaches the end of life, can be incapacitating and difficult to assuage.

An FDA advisory panel voted 8-4 that duvelisib did not have a favorable benefit-risk profile for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who received at least two prior therapies.

It is well known that obesity, physical inactivity and a poor diet increase the risk for various cancer types and contribute to adverse outcomes among adults with certain malignancies.